Literature DB >> 33712527

IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome.

Massimo Cugno1, Silvia Berra2, Federica Depetri3, Silvana Tedeschi4, Samantha Griffini3, Elena Grovetti3, Sonia Caccia2, Donata Cresseri5, Piergiorgio Messa5, Sara Testa6, Fabio Giglio7, Flora Peyvandi3, Gianluigi Ardissino6.   

Abstract

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS), a severe thrombotic microangiopathy, is often related to complement dysregulation, but the pathomechanisms remain unknown in at least 30% of patients. Researchers have described autoantibodies to complement factor H of the IgG class in 10% of patients with aHUS but have not reported anti-factor H autoantibodies of the IgM class.
METHODS: In 186 patients with thrombotic microangiopathy clinically presented as aHUS, we searched for anti-factor H autoantibodies of the IgM class and those of the IgG and IgA classes. We used immunochromatography to purify anti-factor H IgM autoantibodies and immunoenzymatic methods and a competition assay with mapping mAbs to characterize interaction with the target protein.
RESULTS: We detected anti-factor H autoantibodies of the IgM class in seven of 186 (3.8%) patients with thrombotic microangiopathy presented as aHUS. No association was observed between anti-factor H IgM and homozygous deletions involving CFHR3-CFHR1. A significantly higher proportion of patients with bone marrow transplant-related thrombotic microangiopathy had anti-factor H IgM autoantibodies versus other patients with aHUS: three of 20 (15%) versus four of 166 (2.4%), respectively. The identified IgM autoantibodies recognize the SCR domain 19 of factor H molecule in all patients and interact with the factor H molecule, inhibiting its binding to C3b.
CONCLUSIONS: Detectable autoantibodies to factor H of the IgM class may be present in patients with aHUS, and their frequency is six-fold higher in thrombotic microangiopathy forms associated with bone marrow transplant. The autoantibody interaction with factor H's active site may support an autoimmune mechanism in some cases previously considered to be of unknown origin.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  IgM; atypical hemolytic uremic syndrome; autoantibodies; complement; factor H; thrombotic microangiopathy; transplant associated thrombotic microangiopathy

Mesh:

Substances:

Year:  2021        PMID: 33712527      PMCID: PMC8259677          DOI: 10.1681/ASN.2020081224

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  24 in total

1.  Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement.

Authors:  Tommi Kajander; Markus J Lehtinen; Satu Hyvärinen; Arnab Bhattacharjee; Elisa Leung; David E Isenman; Seppo Meri; Adrian Goldman; T Sakari Jokiranta
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-01       Impact factor: 11.205

2.  Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.

Authors:  Marie-Agnès Dragon-Durey; Sidharth Kumar Sethi; Arvind Bagga; Caroline Blanc; Jacques Blouin; Bruno Ranchin; Jean-Luc André; Nobuaki Takagi; Hae Il Cheong; Pankaj Hari; Moglie Le Quintrec; Patrick Niaudet; Chantal Loirat; Wolf Herman Fridman; Véronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 10.121

Review 3.  Haemolytic uraemic syndrome.

Authors:  Fadi Fakhouri; Julien Zuber; Véronique Frémeaux-Bacchi; Chantal Loirat
Journal:  Lancet       Date:  2017-02-25       Impact factor: 79.321

4.  Rapid isolation of pure Complement Factor H from serum for functional studies by the use of a monoclonal antibody that discriminates FH from all the other isoforms.

Authors:  Silvia Berra; Alberto Clivio
Journal:  Mol Immunol       Date:  2016-03-09       Impact factor: 4.407

Review 5.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

6.  Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.

Authors:  Mihály Józsi; Stefanie Strobel; Hans-Martin Dahse; Wei-shih Liu; Peter F Hoyer; Martin Oppermann; Christine Skerka; Peter F Zipfel
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

7.  Autoimmune C1 inhibitor deficiency: report of eight patients.

Authors:  M Cicardi; G Bisiani; M Cugno; P Späth; A Agostoni
Journal:  Am J Med       Date:  1993-08       Impact factor: 4.965

8.  Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Christoph Licht; Jens Goebel; Bradley P Dixon; Kejian Zhang; Theru A Sivakumaran; Stella M Davies; Fred G Pluthero; Lily Lu; Benjamin L Laskin
Journal:  Blood       Date:  2013-06-27       Impact factor: 22.113

Review 9.  Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.

Authors:  Osama Elsallabi; Vijaya Raj Bhatt; Prajwal Dhakal; Kirk W Foster; Ketki K Tendulkar
Journal:  Clin Appl Thromb Hemost       Date:  2015-08-02       Impact factor: 2.389

Review 10.  Autoantibodies in haemolytic uraemic syndrome (HUS).

Authors:  Christine Skerka; Mihály Józsi; Peter F Zipfel; Marie-Agnes Dragon-Durey; Veronique Fremeaux-Bacchi
Journal:  Thromb Haemost       Date:  2009-02       Impact factor: 5.249

View more
  4 in total

1.  Eculizumab treatment in atypical hemolytic uremic syndrome: correlation between functional complement tests and drug levels.

Authors:  Massimo Cugno; Valentina Capone; Samantha Griffini; Elena Grovetti; Giulia Pintarelli; Luigi Porcaro; Emilio Clementi; Gianluigi Ardissino
Journal:  J Nephrol       Date:  2022-01-11       Impact factor: 3.902

2.  Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review.

Authors:  Xiaoyan Wu; Amanda Szarzanowicz; Adinoyi Garba; Beverly Schaefer; Wayne R Waz
Journal:  Cureus       Date:  2021-11-11

Review 3.  Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review.

Authors:  Edward J Filippone; Eric D Newman; Li Li; Rakesh Gulati; John L Farber
Journal:  Front Immunol       Date:  2021-11-10       Impact factor: 7.561

Review 4.  Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy.

Authors:  Gianluigi Ardissino; Valentina Capone; Silvana Tedeschi; Luigi Porcaro; Massimo Cugno
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.